Stopping renin-angiotensin-aldosterone system inhibitors in kidney disease

Curr Opin Nephrol Hypertens. 2026 Mar 16. doi: 10.1097/MNH.0000000000001173. Online ahead of print.ABSTRACTPURPOSE: The KDIGO guidelines recommend the use of renin-angiotensin system inhibitors (RASi) in chronic kidney disease (CKD) given their kidney and cardiovascular benefits. Despite this recomm

E Eva Glenn Lecea

Early changes in kidney function in young adults: what is the significance?

Curr Opin Nephrol Hypertens. 2026 Mar 16. doi: 10.1097/MNH.0000000000001176. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Early changes in kidney function in young adults - particularly modest declines in estimated glomerular filtration rate (eGFR) and the development of microalbuminuria - are i

J Junayd Hussain

A rare encounter mucolipidosis type II alpha/beta: A case report

J Pak Med Assoc. 2026 Feb;76(2):289-292. doi: 10.47391/JPMA.22272.ABSTRACTMucolipidosis type II alpha/beta (ML II) (OMIM # 252500), alternatively referred to as Inclusion Cell (I-cell) Disease, is a relatively rare lysosomal storage disorder that is autosomal recessive in inheritance due to the muta

K Khadija Anwar

The Endocrine Giants of Chronic Kidney Disease

J Pak Med Assoc. 2026 Feb;76(2):269-271. doi: 10.47391/JPMA.26-13.ABSTRACTChronic Kidney Disease (CKD) is increasingly being recognized as an endo-metabolic disorder in which a cascade of hormonal and electrolyte imbalances impacts the morbidity and mortality. We propose six "endocrine giants" of CK

S Sourabh Sharma